OncoGenex Pharmaceuticals, the Bothell, WA-based developer of a prostate cancer drug, said today that its chief financial officer, Stephen Anderson, left the company yesterday. OncoGenex (NASDAQ: [[ticker:OGXI]]) is searching for a replacement, who is “suited for the next stage of company growth, with deep ties in the biopharma investment community and experience transitioning a pharmaceutical company from R&D stage to commercial development,” the company said in a statement. OncoGenex stock closed yesterday at $16.72, down 43 percent since December 21, when it announced a partnership with Teva Pharmaceutical to co-develop its lead drug candidate, OGX-011.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
